SIGNALINK Trademark

Trademark Overview

On Friday, August 2, 2002, a trademark application was filed for SIGNALINK with the United States Patent and Trademark Office. The USPTO has given the SIGNALINK trademark a serial number of 76437733. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, September 24, 2003. This trademark is owned by Atugen AG. The SIGNALINK trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research services in the analysis of signal transduction pathways for use in genetic analysis, target validation, therapeutic intervention, and drug discovery
signalink

General Information

Serial Number76437733
Word MarkSIGNALINK
Filing DateFriday, August 2, 2002
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, September 24, 2003
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesResearch services in the analysis of signal transduction pathways for use in genetic analysis, target validation, therapeutic intervention, and drug discovery
Pseudo MarkSIGNAL INK

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, August 28, 2002
Primary Code042
First Use Anywhere DateMonday, March 11, 2002
First Use In Commerce DateMonday, March 11, 2002

Trademark Owner History

Party NameAtugen AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
Address13125 Berlin
DE

Trademark Events

Event DateEvent Description
Wednesday, September 24, 2003ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, January 15, 2003NON-FINAL ACTION MAILED
Wednesday, December 11, 2002ASSIGNED TO EXAMINER

Related Keywords

signalink analysis therapeutic validation intervention drug discovery target genetic services signal